PTC Therapeutics Stock News

PTC Therapeutics Inc said on Wednesday its experimental Huntington's disease drug lowered mutated protein levels that cause the disease, citing interim data from a mid-stage study.

PTC Therapeutics' (PTCT) vatiquinone did not achieve its primary endpoint in a late-stage study in treating Friedreich Ataxia patients. Shares decline 21% post the news.

PTC Therapeutics (NASDAQ: PTCT ) stock is taking a beating on Wednesday after the company provided investors with an update on a clinical trial. The bad news for PTCT stock is the company's MOVE-FA tr

PTC stock crashed late Tuesday after the company's treatment for a neurological disorder flunked in a Phase 3 study. The post PTC Therapeutics Takes Investors On A Ride With A Failed Study, Scrapped P

Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.

PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan. The post Why PTC Therapeutics Could Be Victorious In Its Rare-Disea

PTC Therapeutics, Inc. (PTCT) Q1 2023 Earnings Call Transcript.

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.78 per share a year ago.

PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced that he is stepping down after 25 years.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Kylie O'Keefe - Chief Commercial Officer Stuart Peltz - Chief Executive Officer

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full y

PTCT is a commercial stage small cap surviving on a timely loan. Their revenue stream is overdependent on one franchise.

PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near